Morgan Stanley Has Lowered Expectations for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price target decreased by research analysts at Morgan Stanley from $301.00 to $285.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the insurance provider’s stock. Morgan Stanley’s price objective suggests a potential upside of 11.03% from the stock’s previous close.

A number of other research firms have also recently commented on HUM. Truist Financial lifted their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, TD Cowen upped their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $296.84.

Humana Stock Down 3.8 %

NYSE:HUM opened at $256.69 on Wednesday. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a market capitalization of $30.91 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average price is $273.00 and its two-hundred day moving average price is $295.72.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts expect that Humana will post 16.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.32% of the company’s stock.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently made changes to their positions in HUM. Pinnacle Wealth Management Advisory Group LLC increased its holdings in Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock worth $272,000 after purchasing an additional 37 shares in the last quarter. Atlas Brown Inc. raised its stake in shares of Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after purchasing an additional 38 shares during the last quarter. Moors & Cabot Inc. lifted its holdings in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after purchasing an additional 40 shares in the last quarter. Mather Group LLC. grew its holdings in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after buying an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC grew its holdings in Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock worth $53,000 after buying an additional 43 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.